The FDA cleared its first blood test to flag prostate cancer in men with high PSA.

An elevated PSA reading has long put men in an uncomfortable position: it signals possible prostate cancer, but it is unreliable enough that acting on it often means an invasive biopsy that turns out to have been unnecessary. Federal regulators have now approved a new blood test built specifically to sharpen that decision point, giving physicians another data source before recommending a biopsy rather than relying on PSA concentration alone.

The approval does not replace the standard PSA test that most men already receive as part of routine screening discussions. It adds a second, more detailed blood analysis for men whose PSA has already come back elevated, aimed at narrowing down who actually needs a biopsy and who can reasonably avoid one.

What the FDA approved

According to reporting from CancerNetwork, the FDA granted premarket approval to IsoPSA, a blood-based diagnostic developed by Cleveland Diagnostics, as an aid for clinicians deciding whether to proceed with a prostate biopsy in men aged 50 and older who present with elevated PSA levels. The approval marks the first time the agency has cleared a blood test built around this specific analytical approach for that particular clinical decision point, rather than simply refining PSA measurement itself.

Premarket approval is the FDA’s most rigorous device clearance pathway, generally reserved for diagnostics where the agency requires the manufacturer to submit clinical data demonstrating the test performs as claimed, rather than showing it is merely similar to an already-cleared product.

How IsoPSA differs from a standard PSA test

A conventional PSA test measures the total concentration of prostate-specific antigen circulating in a patient’s blood. IsoPSA takes a different approach, using a platform called IsoClear to analyze the structural characteristics, or isoforms, of the PSA protein itself, rather than simply counting how much of it is present. That structural analysis is intended to distinguish PSA elevated by aggressive cancer from PSA elevated by other, non-cancerous causes such as an enlarged prostate or inflammation, a distinction that concentration alone cannot reliably make.

That limitation of standard PSA testing has been a persistent problem in prostate cancer screening for years, since elevated PSA can result from several conditions that have nothing to do with cancer, leading to biopsies that ultimately find nothing requiring treatment.

The clinical data behind the approval

The FDA’s decision rested on a prospective, multicenter validation study involving 888 patients who were already scheduled for a prostate biopsy. In that study, IsoPSA achieved an area under the curve of 0.783 for detecting high-grade prostate cancer, along with a sensitivity rate of 90.2%, meaning it correctly identified the large majority of high-grade cancers present in the study population, and a specificity rate of 45.5%.

Based on that performance, researchers involved in the test’s development estimated that using IsoPSA as a decision aid could allow an estimated 46% of high-grade-relevant biopsies and 42% of biopsies overall to be avoided among men classified as low risk by the test, without missing the cancers that actually needed to be found. Additional detail on how FDA device approvals are reviewed and tracked is available through the agency’s device approvals and clearances database.

Why unnecessary biopsies are a bigger problem than people think

The scale of the biopsy-accuracy problem is part of what makes this approval significant. It is estimated that up to 75% of prostate biopsies performed annually in the United States fail to detect high-grade cancer, meaning a large share of men who undergo the procedure endure its discomfort, cost and risk of complications such as bleeding or infection without the test finding the aggressive disease the biopsy was meant to catch.

A test capable of narrowing that pool of biopsy candidates before the procedure, without missing patients who genuinely have aggressive disease, addresses a problem urologists have flagged for years: PSA alone simply is not precise enough to justify sending every man with an elevated reading straight to biopsy.

What it means for men with elevated PSA now

For men who receive an elevated PSA result going forward, the approval means a physician may now have the option to order IsoPSA as an additional step before recommending a biopsy, rather than moving directly from an elevated PSA reading to the procedure itself. Availability will depend on individual healthcare systems adopting the test and insurance coverage decisions that typically follow a new FDA approval, factors that can take time to fall into place even after a test clears federal review.

Men currently facing an elevated PSA result are advised to discuss the full range of available follow-up options with their physician, including whether a test like IsoPSA is appropriate for their specific case, rather than assuming a biopsy is the only next step available once PSA comes back elevated.

Why the approval pathway matters for how fast this reaches patients

Premarket approval is a notably higher bar than the clearance pathway used for many diagnostic tests, and that distinction affects both how much clinical evidence exists behind the test and how quickly it can move into everyday use. Because IsoPSA went through the FDA’s most rigorous device review process, physicians and health systems evaluating whether to adopt it can point to a completed, agency-reviewed clinical validation study rather than a manufacturer’s internal data alone, a factor that often matters to hospital committees and insurers deciding whether to cover a new test.

That same rigor, however, typically means adoption unfolds gradually rather than immediately following approval. Individual hospital systems and physician practices generally need to establish their own protocols for ordering and interpreting a newly approved test, and insurance coverage decisions can lag behind FDA approval by months or longer. Men interested in the test soon after its approval may find availability varies significantly depending on their region and healthcare system, even though the underlying FDA clearance already applies nationwide.

Morning Overview produced this article with AI assistance and reviewed it against the cited sources.

More from Morning Overview